You are here: Industry Insights > Treatment

News List

Psychotherapy Alone First Line of Treatment for Depressed Youth drugs
August 13, 2019
Cognitive behavioral therapy (CBT) should be the first line of treatment in younger patients with major depressive disorder before clinicians prescribe medication...
FDA grants Orphan Drug Designation to DYN101 treatment europeanpharmaceuticalreview
August 13, 2019
A treatment for Centronuclear Myopathies has received Orphan Drug Designation from the FDA and will begin Phase I/II trials.
Increasing Number of Diseases Causing Alopecia Boosts Treatment Market europeanpharmaceuticalreview
August 12, 2019
The global alopecia treatment market is projected to exhibit a CAGR of 4.9 percent from 2018–2026.
Don't Sweat It: Hyperhydrosis Can Be Treated drugs
August 08, 2019
There's nothing more embarrassing than sweating profusely in public places, yet one expert says many people suffer through the humiliation for decades.
Metastatic melanoma treatment gets Breakthrough Therapy Designation europeanpharmaceuticalreview
August 06, 2019
Breakthrough Therapy Designation has been granted for investigational agent bempegaldesleukin in combination with nivolumab.
Common Prostate Cancer Treatment Anti-Androgens May Increase Risk of Fatal Heart Condition drugs
August 06, 2019
Many men with prostate cancer rely on common testosterone-blocking drugs as a part of their treatment.
NICE recommends Lokelma treatment for hyperkalaemia europeanpharmaceuticalreview
August 05, 2019
Lokelma, a treatment for hyperkalaemia in adults, has received a positive Final Appraisal Document from NICE after successful trials.
Finances Affect Women's Choice of Breast Cancer Treatment: Study drugs
August 05, 2019
Cost often influences breast cancer patients' decisions about surgery, even if they have good incomes and insurance, a new study finds.
Smoking May Interfere With 'Embolization' Lung Treatment drugs
July 31, 2019
Here's yet another downside to cigarette smoking: Treatment for blood vessel abnormalities in the lungs is less likely to be successful if patients are smokers...
Relmada Completes Dosing of REL-1017 in Phase 2 of Treatment Resistant Depression Study americanpharmaceuticalreview
July 30, 2019
Relmada Therapeutics announced the last subject has completed dosing with REL-1017 (dextromethadone) in the company's double-blind, placebo-controlled Phase 2 clinical study evaluating the safety and efficacy of REL-1017 as ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page